Abstract LB-140: An innovative approach for profiling of histone modification marks and gene expression across a panel of oncogenes and tumor suppressor genes in multiple cancer cell lines

Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC Objectives: Histone modification marks and gene expression profiling on multiple human oncogenes and tumor suppressor genes to study the correlation between epigenetic modifications and gene expression in cancer cells derived from different tissue/cell types. Methodology: Chromatin Immunoprecipitation (ChIP) was performed on the isolated chromatin samples from various cancer cell lines (MCF7, A549, HepG2, HCT116, PC3 and HeLa) using antibodies against H3K4me2, H3K4me3, H3Ac, H3K27me3, H3K9me3, H4K20me3, and RNA Pol II. Each resulting ChIP DNA fraction was analyzed with a ChIP Real-Time PCR Array consisting of specific PCR primers targeting the downstream region of the transcription start site (within + 1Kb). For this study 84 oncogenes & tumor suppressor genes were measured simultaneously along with control gene regions characteristic for each histone modification. Real-time RT-PCR Arrays were also employed to analyze the mRNA levels for all 84 genes in the same 6 cancer cell lines. These results allow analysis to correlate specific histone marks with the transcript levels. Results: The data indicate a much more complex correlation between modified histone marks and gene expression across different cancer cell lines. The results provide insights into the complex epigenetic regulation in cancer cells. The combination of ChIP-qPCR Arrays (histone modifications) and RT-qPCR Arrays to study multiple oncogenes and tumor suppressor genes simultaneously in various cancer samples should prove a valuable and fast approach in the assessment of the correlation between epigenetic regulation and clinical characteristics. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-140.